InsidersTradesSigma
Track the STOKE THERAPEUTICS INC share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2bn. The latest transaction was reported on 1 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: BARUCH S. TICHO. All data is accessible without an account.
Analysts rate STOKE THERAPEUTICS INC Strong Buy (bullish), based on 13 analysts. Average price target: US$46.46.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
STOKE THERAPEUTICS INC es una empresa biofarmacéutica centrada en el desarrollo de terapias para tratar enfermedades genéticas. Emplea un enfoque innovador para modular la expresión génica y corregir defectos genéticos.